PT - JOURNAL ARTICLE AU - Delaney Burnard AU - Letitia Gore AU - Andrew Henderson AU - Ama Ranasinghe AU - Haakon Bergh AU - Kyra Cottrell AU - Derek S. Sarovich AU - Erin P. Price AU - David L. Paterson AU - Patrick N. A. Harris TI - Comparative genomics and antimicrobial resistance profiling of <em>Elizabethkingia</em> isolates reveals nosocomial transmission and <em>in vitro</em> susceptibility to fluoroquinolones, tetracyclines and trimethoprim-sulfamethoxazole AID - 10.1101/2020.03.12.20032722 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.12.20032722 4099 - http://medrxiv.org/content/early/2020/03/31/2020.03.12.20032722.short 4100 - http://medrxiv.org/content/early/2020/03/31/2020.03.12.20032722.full AB - The Elizabethkingia genus has gained global attention in recent years as a nosocomial pathogen. Elizabethkingia spp. are intrinsically multidrug resistant, primarily infect immunocompromised individuals, and are associated with high mortality (∼20-40%). Although Elizabethkingia infections appear sporadically worldwide, gaps remain in our understanding of transmission, global strain relatedness and patterns of antimicrobial resistance. To address these knowledge gaps, 22 clinical isolates collected in Queensland, Australia, over a 16-year period along with six hospital environmental isolates were examined using MALDI-TOF MS (VITEK® MS) and whole-genome sequencing to compare with a global strain dataset. Phylogenomic reconstruction against all publicly available genomes (n=100) robustly identified 22 E. anophelis, three E. miricola, two E. meningoseptica and one E. bruuniana from our isolates, most with previously undescribed diversity. Global relationships show Australian E. anophelis isolates are genetically related to those from the USA, England and Asia, suggesting shared ancestry. Genomic examination of clinical and environmental strains identified evidence of nosocomial transmission in patients admitted several months apart, indicating probable infection from a hospital reservoir. Furthermore, broth microdilution of the 22 clinical Elizabethkingia spp. isolates against 39 antimicrobials revealed almost ubiquitous resistance to aminoglycosides, carbapenems, cephalosporins and penicillins, but susceptibility to minocycline, levofloxacin and trimethoprim/sulfamethoxazole. Our study demonstrates important new insights into the genetic diversity, environmental persistence and transmission of Australian Elizabethkingia species. Furthermore, we show that Australian isolates are highly likely to be susceptible to minocycline, levofloxacin and trimethoprim/sulfamethoxazole, suggesting that these antimicrobials may provide effective therapy for Elizabethkingia infections.Importance Elizabethkingia are a genus of environmental Gram-negative, multidrug resistant, opportunistic pathogens. Although an uncommon cause of nosocomial and community-acquired infections, Elizabethkingia spp. are known to infect those with underlying co-morbidities and/or immunosuppression, with high mortality rates of ∼20-40%. Elizabethkingia have a presence in Australian hospitals and patients; however, their origin, epidemiology, and antibiotic resistance profile of these strains is poorly understood. Here, we performed phylogenomic analyses of clinical and hospital environmental Australian Elizabethkingia spp., to understand transmission and global relationships. Next, we performed extensive minimum inhibitory concentration testing to determine antimicrobial susceptibility profiles. Our findings identified a highly diverse Elizabethkingia population in Australia, with many being genetically related to international strains. A potential transmission source was identified within the hospital environment where two transplant patients were infected and three E. anophelis strains formed a clonal cluster within the phylogeny. Furthermore, near ubiquitous susceptibility to tetracyclines, fluoroquinolones and trimethoprim/sulfamethoxazole was observed in clinical isolates. We provide new insights into the origins, transmission and epidemiology of Elizabethkingia spp., in addition to understanding their intrinsic resistance profiles and potential effective treatment options, which has implications to managing infections and detecting outbreaks globally.Competing Interest StatementDr. Paterson reports grants from National Health and Medical Research Council, non-financial support from Ecolab Pty Ltd, non-financial support from Whiteley Corporation, non-financial support from Kimberly-Clark Professional, during the conduct of the study; personal fees from Merck, Shionogi, Achaogen, AstraZeneca, Leo Pharmaceuticals, Bayer, GlazoSmithKline, Cubist, Venatorx, Accelerate; grants from Shionogi, Merck (MSD), personal fees from Pfizer, outside the submitted work. Dr. Harris reports grants from Merck (MSD) and Shionogi, personal fees from Pfizer, outside the submitted work. All other authors declare no conflicts of interest.Funding StatementFunding: Study Education and Research Committee of Pathology Queensland (LG), University of the Sunshine Coast (DB), Advance Queensland (AQRF13016-17RD2 for DSS; AQIRF0362018 for EPP), and the National Health and Medical Research Council (GNT1157530 for PNAH).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIllumina sequence data for the 28 Elizabethkingia spp. genomes described in this study have been deposited in the NCBI SRA database under identifier SRP225137, BioProject PRJNA576977 (BioSample accessions: SAMN13016226-SAMN13016247 and SAMN14081590- SAMN14081595). https://www.ncbi.nlm.nih.gov/bioproject/PRJNA576977